Novo NordiskSee all their emails

FREHEMGO® (denecimig) approved in the EU for haemophilia A, with a choice of monthly, every-two-weeks or weekly dosing

A real announcement email from Novo Nordisk. Captured November 13, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

FREHEMGO® (denecimig) approved in the EU for haemophilia A, with a choice of monthly, every-two-weeks or weekly dosing email from Novo Nordisk screenshot

Captured Announcement

Novo Nordisk announces European Commission marketing authorisation for FREHEMGO (denecimig) for routine prophylaxis in haemophilia A.

Standard corporate press release layout featuring a top logo, bulleted key highlights, comprehensive press body text, media/investor contacts table, and citations.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.